{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:23:10Z","timestamp":1790716990481,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Penile acquisition of HIV accounts for most infections among men globally. Nevertheless, candidate HIV interventions for men advance to clinical trials without preclinical efficacy data, due primarily to a paucity of relevant animal models of penile HIV infection. Using our recently developed macaque model, we show that a single subcutaneous administration of broadly neutralizing antibody (bNAb) 10-1074 conferred durable protection against repeated penile exposures to simian-human immunodeficiency virus (SHIV<jats:sub>SF162P3<\/jats:sub>). Macaques co-administered bNAbs 10-1074 and 3BNC117, or 3BNC117 alone, also exhibited significant protection against repeated vaginal SHIV<jats:sub>AD8-EO<\/jats:sub> exposures. Regression modeling estimated that individual plasma bNAb concentrations of 5\u2009\u03bcg\u2009ml<jats:sup>\u22121<\/jats:sup> correlated with\u2009\u226599.9% relative reduction in SHIV infection probability via penile (10-1074) or vaginal (10-1074 or 3BNC117) challenge routes. These results demonstrate that comparably large reductions in penile and vaginal SHIV infection risk among macaques were achieved at clinically relevant plasma bNAb concentrations and inform dose selection for the development of bNAbs as long-acting pre-exposure prophylaxis candidates for use by men and women.<\/jats:p>","DOI":"10.1038\/s41467-020-16928-9","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T10:02:52Z","timestamp":1592992972000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Durable protection against repeated penile exposures to simian-human immunodeficiency virus by broadly neutralizing antibodies"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3608-7104","authenticated-orcid":false,"given":"David A.","family":"Garber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra R.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Guenthner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Schoofs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Gazumyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Nason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"McNicholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel C.","family":"Nussenzweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Heneine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"key":"16928_CR1","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1097\/QAD.0000000000000298","volume":"28","author":"P Patel","year":"2014","unstructured":"Patel, P. et al. Estimating per-act HIV transmission risk: a systematic review. AIDS 28, 1509\u20131519 (2014).","journal-title":"AIDS"},{"key":"16928_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1586\/14737167.2016.1102635","volume":"16","author":"FK Giannou","year":"2016","unstructured":"Giannou, F. K. et al. Condom effectiveness in reducing heterosexual HIV transmission: a systematic review and meta-analysis of studies on HIV serodiscordant couples. Expert Rev. Pharmacoecon. Outcomes Res. 16, 489\u2013499 (2016).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"16928_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten, J. M. et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367, 399\u2013410 (2012).","journal-title":"N. Engl. J. Med."},{"key":"16928_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJMoa1110711","volume":"367","author":"MC Thigpen","year":"2012","unstructured":"Thigpen, M. C. et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N. Engl. J. Med. 367, 423\u2013434 (2012).","journal-title":"N. Engl. J. Med."},{"key":"16928_CR5","first-page":"Cd003362","volume":"2","author":"N Siegfried","year":"2009","unstructured":"Siegfried N., Muller M., Deeks J. J., Volmink J. Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst. Rev. 2, Cd003362 (2009).","journal-title":"Cochrane Database Syst. Rev."},{"key":"16928_CR6","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant, R. M. et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. The. N. Engl. J. Med. 363, 2587\u20132599 (2010).","journal-title":"N. Engl. J. Med."},{"key":"16928_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","volume":"387","author":"S McCormack","year":"2016","unstructured":"McCormack, S. et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 387, 53\u201360 (2016).","journal-title":"Lancet"},{"key":"16928_CR8","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","volume":"373","author":"JM Molina","year":"2015","unstructured":"Molina, J. M. et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N. Engl. J. Med. 373, 2237\u20132246 (2015).","journal-title":"N. Engl. J. Med."},{"key":"16928_CR9","doi-asserted-by":"crossref","unstructured":"Chou, R. et al. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. In: Pre-Exposure Prophylaxis for the Prevention of HIV Infection: A Systematic Review for the U.S. Preventive Services Task Force (Agency for Healthcare Research and Quality, US, 2019).","DOI":"10.1001\/jama.2019.2591"},{"key":"16928_CR10","doi-asserted-by":"publisher","unstructured":"Gilbert, P. B. et al. Basis and statistical design of the passive HIV-1 antibody mediated prevention (AMP) test-of-concept efficacy trials. Stat. Commun. Infect. Dis. 9, https:\/\/doi.org\/10.1515\/scid-2016-0001 (2017).","DOI":"10.1515\/scid-2016-0001"},{"key":"16928_CR11","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1097\/QAD.0b013e32832baa34","volume":"23","author":"PS Sullivan","year":"2009","unstructured":"Sullivan, P. S., Salazar, L., Buchbinder, S. & Sanchez, T. H. Estimating the proportion of HIV transmissions from main sex partners among men who have sex with men in five US cities. AIDS 23, 1153\u20131162 (2009).","journal-title":"AIDS"},{"key":"16928_CR12","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41591-019-0412-8","volume":"25","author":"M Caskey","year":"2019","unstructured":"Caskey, M., Klein, F. & Nussenzweig, M. C. Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nat. Med. 25, 547\u2013553 (2019).","journal-title":"Nat. Med."},{"key":"16928_CR13","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s41590-018-0235-7","volume":"19","author":"D Sok","year":"2018","unstructured":"Sok, D. & Burton, D. R. Recent progress in broadly neutralizing antibodies to HIV. Nat. Immunol. 19, 1179\u20131188 (2018).","journal-title":"Nat. Immunol."},{"key":"16928_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.coviro.2019.07.007","volume":"38","author":"M Grobben","year":"2019","unstructured":"Grobben, M., Stuart, R. A. & van Gils, M. J. The potential of engineered antibodies for HIV-1 therapy and cure. Curr. Opin. Virol. 38, 70\u201380 (2019).","journal-title":"Curr. Opin. Virol."},{"key":"16928_CR15","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1126\/science.1207227","volume":"333","author":"JF Scheid","year":"2011","unstructured":"Scheid, J. F. et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633\u20131637 (2011).","journal-title":"Science"},{"key":"16928_CR16","doi-asserted-by":"publisher","first-page":"E3268","DOI":"10.1073\/pnas.1217207109","volume":"109","author":"H Mouquet","year":"2012","unstructured":"Mouquet, H. et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl. Acad. Sci. USA 109, E3268\u2013E3277 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"16928_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nm.4268","volume":"23","author":"M Caskey","year":"2017","unstructured":"Caskey, M. et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat. Med. 23, 185\u2013191 (2017).","journal-title":"Nat. Med."},{"key":"16928_CR18","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nature14411","volume":"522","author":"M Caskey","year":"2015","unstructured":"Caskey, M. et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487\u2013491 (2015).","journal-title":"Nature"},{"key":"16928_CR19","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nature18929","volume":"535","author":"JF Scheid","year":"2016","unstructured":"Scheid, J. F. et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 535, 556\u2013560 (2016).","journal-title":"Nature"},{"key":"16928_CR20","doi-asserted-by":"publisher","first-page":"e0219142","DOI":"10.1371\/journal.pone.0219142","volume":"14","author":"YZ Cohen","year":"2019","unstructured":"Cohen, Y. Z. et al. Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: a randomized, phase 1 study. PloS One 14, e0219142 (2019).","journal-title":"PloS One"},{"key":"16928_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/COH.0000000000000152","volume":"10","author":"AJ Hessell","year":"2015","unstructured":"Hessell, A. J. & Haigwood, N. L. Animal models in HIV-1 protection and therapy. Curr. Opin. HIV AIDS 10, 170\u2013176 (2015).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"16928_CR22","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1097\/QAD.0000000000001521","volume":"31","author":"DJ Anderson","year":"2017","unstructured":"Anderson, D. J. et al. Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV. AIDS 31, 1505\u20131517 (2017).","journal-title":"AIDS"},{"key":"16928_CR23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nature17677","volume":"533","author":"R Gautam","year":"2016","unstructured":"Gautam, R. et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 533, 105\u2013109 (2016).","journal-title":"Nature"},{"key":"16928_CR24","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1084\/jem.20132494","volume":"211","author":"M Shingai","year":"2014","unstructured":"Shingai, M. et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med. 211, 2061\u20132074 (2014).","journal-title":"J. Exp. Med."},{"key":"16928_CR25","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1600-0897.2010.00941.x","volume":"65","author":"D Anderson","year":"2011","unstructured":"Anderson, D., Politch, J. A. & Pudney, J. HIV infection and immune defense of the penis. Am. J. Reprod. Immunol. 65, 220\u2013229 (2011).","journal-title":"Am. J. Reprod. Immunol."},{"key":"16928_CR26","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/aji.12230","volume":"71","author":"DJ Anderson","year":"2014","unstructured":"Anderson, D. J., Marathe, J. & Pudney, J. The structure of the human vaginal stratum corneum and its role in immune defense. Am. J. Reprod. Immunol. 71, 618\u2013623 (2014).","journal-title":"Am. J. Reprod. Immunol."},{"key":"16928_CR27","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nri2302","volume":"8","author":"F Hladik","year":"2008","unstructured":"Hladik, F. & McElrath, M. J. Setting the stage: host invasion by HIV. Nat. Rev. Immunol. 8, 447\u2013457 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"16928_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25300","volume":"22","author":"SS Abdool Karim","year":"2019","unstructured":"Abdool Karim, S. S., Baxter, C., Passmore, J. S., McKinnon, L. R. & Williams, B. L. The genital tract and rectal microbiomes: their role in HIV susceptibility and prevention in women. J. Int. AIDS Soc. 22, e25300 (2019).","journal-title":"J. Int. AIDS Soc."},{"key":"16928_CR29","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.cll.2014.08.005","volume":"34","author":"JT Salas","year":"2014","unstructured":"Salas, J. T. & Chang, T. L. Microbiome in human immunodeficiency virus infection. Clin. Lab. Med. 34, 733\u2013745 (2014).","journal-title":"Clin. Lab. Med."},{"key":"16928_CR30","doi-asserted-by":"publisher","first-page":"11388","DOI":"10.1128\/JVI.01377-13","volume":"87","author":"AM Carias","year":"2013","unstructured":"Carias, A. M. et al. Defining the interaction of HIV-1 with the mucosal barriers of the female reproductive tract. J. Virol. 87, 11388\u201311400 (2013).","journal-title":"J. Virol."},{"key":"16928_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1095\/biolreprod.111.094789","volume":"86","author":"MH Dinh","year":"2012","unstructured":"Dinh, M. H., Okocha, E. A., Koons, A., Veazey, R. S. & Hope, T. J. Expression of structural proteins in human female and male genital epithelia and implications for sexually transmitted infections. Biol. Reprod. 86, 32 (2012).","journal-title":"Biol. Reprod."},{"key":"16928_CR32","doi-asserted-by":"publisher","first-page":"e1004729","DOI":"10.1371\/journal.ppat.1004729","volume":"11","author":"MH Dinh","year":"2015","unstructured":"Dinh, M. H. et al. Visualization of HIV-1 interactions with penile and foreskin epithelia: clues for female-to-male HIV transmission. PLoS Pathog. 11, e1004729 (2015).","journal-title":"PLoS Pathog."},{"key":"16928_CR33","doi-asserted-by":"publisher","first-page":"e0194837","DOI":"10.1371\/journal.pone.0194837","volume":"13","author":"DA Garber","year":"2018","unstructured":"Garber, D. A. et al. Development of a repeat-exposure penile SHIV infection model in macaques to evaluate biomedical preventions against HIV. PloS one 13, e0194837 (2018).","journal-title":"PloS one"},{"key":"16928_CR34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/COH.0000000000000534","volume":"14","author":"N Bbosa","year":"2019","unstructured":"Bbosa, N., Kaleebu, P. & Ssemwanga, D. HIV subtype diversity worldwide. Curr. Opin. HIV AIDS 14, 153\u2013160 (2019).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"16928_CR35","doi-asserted-by":"publisher","first-page":"e1005520","DOI":"10.1371\/journal.ppat.1005520","volume":"12","author":"K Wagh","year":"2016","unstructured":"Wagh, K. et al. Optimal combinations of broadly neutralizing antibodies for prevention and treatment of HIV-1 Clade C infection. PLoS Pathog. 12, e1005520 (2016).","journal-title":"PLoS Pathog."},{"key":"16928_CR36","doi-asserted-by":"publisher","first-page":"e1006860","DOI":"10.1371\/journal.ppat.1006860","volume":"14","author":"K Wagh","year":"2018","unstructured":"Wagh, K. et al. Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. PLoS Pathog. 14, e1006860 (2018).","journal-title":"PLoS Pathog."},{"key":"16928_CR37","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1128\/JVI.06745-11","volume":"86","author":"NA Doria-Rose","year":"2012","unstructured":"Doria-Rose, N. A. et al. HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. J. Virol. 86, 3393\u20133397 (2012).","journal-title":"J. Virol."},{"key":"16928_CR38","doi-asserted-by":"publisher","first-page":"10857","DOI":"10.1128\/JVI.01414-12","volume":"86","author":"L Goo","year":"2012","unstructured":"Goo, L., Jalalian-Lechak, Z., Richardson, B. A. & Overbaugh, J. A combination of broadly neutralizing HIV-1 monoclonal antibodies targeting distinct epitopes effectively neutralizes variants found in early infection. J. Virol. 86, 10857\u201310861 (2012).","journal-title":"J. Virol."},{"key":"16928_CR39","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1128\/JVI.03136-14","volume":"89","author":"R Kong","year":"2015","unstructured":"Kong, R. et al. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. J. Virol. 89, 2659\u20132671 (2015).","journal-title":"J. Virol."},{"key":"16928_CR40","doi-asserted-by":"publisher","unstructured":"Julg, B. et al. Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. Sci. Transl. Med. 9, https:\/\/doi.org\/10.1126\/scitranslmed.aao4235 (2017).","DOI":"10.1126\/scitranslmed.aao4235"},{"key":"16928_CR41","doi-asserted-by":"publisher","first-page":"112736","DOI":"10.1016\/j.jim.2020.112736","volume":"479","author":"MS Seaman","year":"2020","unstructured":"Seaman, M. S. et al. Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bNAbs. J. Immunolog. Methods 479, 112736\u2013112746 (2020).","journal-title":"J. Immunolog. Methods"},{"key":"16928_CR42","doi-asserted-by":"publisher","first-page":"112764","DOI":"10.1016\/j.jim.2020.112764","volume":"479","author":"Bharadwaj","year":"2020","unstructured":"Bharadwaj et al. Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies. J. Immunolog. Methods 479, 112764\u2013112775 (2020).","journal-title":"J. Immunolog. Methods"},{"key":"16928_CR43","first-page":"S125","volume":"14","author":"S Hild-Petito","year":"1998","unstructured":"Hild-Petito, S., Veazey, R. S., Larner, J. M., Reel, J. R. & Blye, R. P. Effects of two progestin-only contraceptives, Depo-Provera and Norplant-II, on the vaginal epithelium of rhesus monkeys. AIDS Res. Hum. Retrovir. 14, S125\u2013S130 (1998).","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"16928_CR44","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/nm1096-1084","volume":"2","author":"PA Marx","year":"1996","unstructured":"Marx, P. A. et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat. Med. 2, 1084\u20131089 (1996).","journal-title":"Nat. Med."},{"key":"16928_CR45","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nm833","volume":"9","author":"RS Veazey","year":"2003","unstructured":"Veazey, R. S. et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9, 343\u2013346 (2003).","journal-title":"Nat. Med."},{"key":"16928_CR46","unstructured":"UNAIDS. UNAIDS Data 2019. 16\u201318 (Joint United Nations Programme on HIV\/AIDS, Geneva, Switzerland, 2019)."},{"key":"16928_CR47","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1097\/QAD.0000000000001102","volume":"30","author":"B Moldt","year":"2016","unstructured":"Moldt, B. et al. Neutralizing antibody affords comparable protection against vaginal and rectal simian\/human immunodeficiency virus challenge in macaques. AIDS 30, 1543\u20131551 (2016).","journal-title":"AIDS"},{"key":"16928_CR48","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nri1706","volume":"5","author":"AT Haase","year":"2005","unstructured":"Haase, A. T. Perils at mucosal front lines for HIV and SIV and their hosts. Nat. Rev. Immunol. 5, 783\u2013792 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"16928_CR49","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1126\/science.aag0491","volume":"353","author":"J Liu","year":"2016","unstructured":"Liu, J. et al. Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus. Science 353, 1045\u20131049 (2016).","journal-title":"Science"},{"key":"16928_CR50","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nature13612","volume":"514","author":"SY Ko","year":"2014","unstructured":"Ko, S. Y. et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514, 642\u2013645 (2014).","journal-title":"Nature"},{"key":"16928_CR51","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/mi.2015.103","volume":"9","author":"MP Lemos","year":"2016","unstructured":"Lemos, M. P. et al. In men at risk of HIV infection, IgM, IgG1, IgG3, and IgA reach the human foreskin epidermis. Mucosal Immunol. 9, 798\u2013808 (2016).","journal-title":"Mucosal Immunol."},{"key":"16928_CR52","unstructured":"Male Circumcision: Global Trends and Determinants of Prevalence, Safety and Acceptability (World Health Organization, 2007) https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/43749\/9789241596169_enf.pdf;jsessionid=0410849DFA1EE6E3E7877F0D06B0F820?sequence=1."},{"key":"16928_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12963-016-0073-5","volume":"14","author":"BJ Morris","year":"2016","unstructured":"Morris, B. J. et al. Estimation of country-specific and global prevalence of male circumcision. Popul. Health Metr. 14, 4 (2016).","journal-title":"Popul. Health Metr."},{"key":"16928_CR54","doi-asserted-by":"publisher","first-page":"e298","DOI":"10.1371\/journal.pmed.0020298","volume":"2","author":"B Auvert","year":"2005","unstructured":"Auvert, B. et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2, e298 (2005).","journal-title":"PLoS Med."},{"key":"16928_CR55","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S0140-6736(07)60312-2","volume":"369","author":"RC Bailey","year":"2007","unstructured":"Bailey, R. C. et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369, 643\u2013656 (2007).","journal-title":"Lancet"},{"key":"16928_CR56","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0140-6736(07)60313-4","volume":"369","author":"RH Gray","year":"2007","unstructured":"Gray, R. H. et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369, 657\u2013666 (2007).","journal-title":"Lancet"},{"key":"16928_CR57","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1097\/01.aids.0000237364.11123.98","volume":"20","author":"SG McCoombe","year":"2006","unstructured":"McCoombe, S. G. & Short, R. V. Potential HIV-1 target cells in the human penis. AIDS 20, 1491\u20131495 (2006).","journal-title":"AIDS"},{"key":"16928_CR58","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/QAD.0b013e328321b778","volume":"23","author":"L Fischetti","year":"2009","unstructured":"Fischetti, L., Barry, S. M., Hope, T. J. & Shattock, R. J. HIV-1 infection of human penile explant tissue and protection by candidate microbicides. AIDS 23, 319\u2013328 (2009).","journal-title":"AIDS"},{"key":"16928_CR59","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1086\/507306","volume":"194","author":"S Subbarao","year":"2006","unstructured":"Subbarao, S. et al. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J. Infect. Dis. 194, 904\u2013911 (2006).","journal-title":"J. Infect. Dis."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-16928-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-16928-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-16928-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T23:31:28Z","timestamp":1670283088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-16928-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["16928"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-16928-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,24]]},"assertion":[{"value":"21 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are patents on 3BNC117 (US Provisional Application No. 61\/715,642) and 10\u20131074 (US Provisional Application No. 61\/486,960) on which MCN is an inventor. 10\u20131074 and 3BNC117 are included in licensing agreements between The Rockefeller University and Gilead Sciences. The authors declare no further competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3195"}}